Drug Discovery & DDS– category –
-
BRD4-Targeting PROTAC Nanoassemblies Dramatically Enhance FLASH Radiotherapy, Achieving Robust Tumor Suppression
PMC USA Overview New research reveals that BRD4-targeting PROTAC nanoassemblies (APF) significantly amplify the anti-tumor efficacy of ultra-high dose rate FLASH radiotherapy (FLASH-RT). By efficiently delivering the BRD4 degrader ARV-77... -
Smart Hydrogel-Nanoparticle Platforms Pioneer Precision Drug Delivery and TME Modulation in Breast Cancer
ACS Publications USA Overview A recent paper in ACS Publications unveils a smart hydrogel-nanoparticle platform poised to revolutionize breast cancer treatment through precise drug delivery and tumor microenvironment (TME) modulation. Th... -
AbbVie’s Etentamig: A Next-Generation Bispecific Engager Set to Redefine Multiple Myeloma Treatment
Fierce Biotech USA Overview AbbVie has announced positive Phase 3 clinical trial results for etentamig, a second-generation bispecific T-cell engager, in patients with relapsed/refractory multiple myeloma (RRMM). Targeting BCMA and CD3, ... -
Democratizing Advanced Immunotherapy: BiTE Therapies Expand into Community Cancer Centers
American Oncology Network USA Overview Bispecific T-cell Engager (BiTE) therapy represents a significant breakthrough in cancer treatment, now experiencing expanding adoption within community oncology facilities across the United States.... -
Advanced TME Models Unlock Novel Strategies for Enhanced ADC Therapy
Journal for ImmunoTherapy of Cancer USA Overview A recent study published in the Journal for ImmunoTherapy of Cancer modeled how the tumor immune microenvironment (TME) impedes the delivery and efficacy of antibody-drug conjugates (ADCs)... -
FDA Grants Fast Track Designation to Four Novel Cancer Therapeutics, Accelerating Development for Urgent Needs
Targeted Oncology USA Overview In August 2026, the U.S. FDA granted Fast Track designation to four novel oncology drugs, significantly accelerating their development and review processes. These include Erasca Inc.'s ERAS-0015 (pancreatic... -
AI and Advanced Pharma Tech Converge: Insilico’s INS018_055 Achieves Clinical Success
MDPI Switzerland Overview Artificial intelligence and machine learning are revolutionizing pharmaceutical R&D by integrating with advanced technologies like pharmacogenomics and organ-on-a-chip systems. AI-designed drugs, such as Ins... -
Unlocking TPD’s Promise: Nanomedicine and Programmable Proximity Platforms Revolutionize Degrader Delivery
MDPI Switzerland Overview Nanomedicine and programmable proximity platforms are emerging as pivotal solutions to the delivery challenges inherent in targeted protein degradation (TPD) technologies. Degrader molecules like PROTACs often f... -
Redefining Colorectal Cancer Treatment: Breakthroughs in Bispecific Antibodies and ADCs
MDPI Switzerland Overview Bispecific antibodies (bsAbs) and antibody-drug conjugates (bsADCs) are ushering in a new era for colorectal cancer (CRC) treatment, offering solutions to challenges like tumor heterogeneity and drug resistance.... -
Generative AI & Quantum Computing Converge to Revolutionize Inverse Design for Molecules and Materials
SEMICON Taiwan Taiwan Overview Generative AI is enabling a transformative "inverse design" approach, directly generating molecular and material structures with desired properties, thereby fundamentally reshaping drug discovery and materi...
